Another blow to Obamacare as Anthem threatens to pull out of exchanges

31 March 2017

Jubilant Democrats may have to put the champagne cork back in the bottle - the Affordable Care Act (ACA) - Obamacare - isn't out of the woods just yet.

Weeks after healthcare giant Humana withdrew from the state health insurance exchanges set up under Obamacare, another major insurer is rumored to be following suit.

The Washington Post reported that Anthem was “leaning towards exiting” many parts of the exchanges, citing Wall Street analysts who met with the company. Anthem currently has over 800,000 members enrolled through exchanges in 14 states.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK